廣譽遠(600771.SH):子公司擬250萬元購買拉薩廣譽遠5%股權
格隆匯 8 月 12日丨廣譽遠(600771.SH)公佈,公司控股子公司山西廣譽遠國藥有限公司(“山西廣譽遠”)擬以現金方式購買關聯人張斌持有拉薩東盛廣譽遠藥業有限公司(“拉薩廣譽遠”)5%的股權。交易金額:250萬元人民幣。
此次交易完成後,拉薩廣譽遠將成為山西廣譽遠的全資子公司,此次交易有助於進一步增強山西廣譽遠的盈利能力以及對下屬子公司的管控能力,有效優化公司股權及業務結構,完善資源配置,增強內部協同,提升公司管理和運營效率。此次交易對山西廣譽遠和公司未來財務狀況和經營成果將帶來積極影響,有利於公司長遠發展,符合全體股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.